Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

The Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes

(2017) David P. Steensma   Journal of the National Comprehensive Cancer Network

Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population

(2012) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

(2012) N. Gattermann et al.   HAEMATOLOGICA

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry

(2011) Judith Neukirchen et al.   LEUKEMIA RESEARCH

Iron overload in MDS—pathophysiology, diagnosis, and complications

(2010) Norbert Gattermann et al.   ANNALS OF HEMATOLOGY

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

(2010) J. W. Lee et al.   BLOOD

Molecular mechanisms involved in the progression of myelodysplastic syndrome

(2010) Florian Nolte et al.   Future Oncology

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes

(2010) Peter L. Greenberg et al.   LEUKEMIA RESEARCH

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Consensus statement on iron overload in myelodysplastic syndromes

(2008) John M. Bennett et al.   AMERICAN JOURNAL OF HEMATOLOGY

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

(2008) Jelena M. Kao et al.   AMERICAN JOURNAL OF HEMATOLOGY